Ultra-micronized PEA Selective Antiproliferative Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for colorectal cancer lack effective preventive measures that selectively target cancer cells without harming healthy cells, and existing treatments often involve harmful chemicals that affect both diseased and healthy cells.
Innovation Solution
The use of ultra-micronized palmitoylethanolamide (PEA) in pharmaceutical or veterinary formulations for oral administration, which exerts a selective antiproliferative action on tumor cells, specifically targeting the activation and proliferation phases of colorectal carcinoma, adenomatous polyps, and pre-neoplastic ACF lesions, while sparing healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy treatment is used to treat colorectal cancer, then cancer cells are targeted and destroyed, but healthy cells are also harmed
Solution Approach 1:
The patent applies local quality by making the anti-proliferative effect of PEA selective for neoplastic cells rather than uniform across all cells. The substance exhibits different biological activities depending on the cell type: it strongly inhibits neoplastic cell proliferation while having minimal effect on healthy cells, creating a localized therapeutic effect at the molecular/biological level.
2Reliability
If chemo-prevention is used to prevent colorectal cancer, then carcinogenesis is interrupted, but selective action on cancer cells without affecting healthy cells is lacking
Solution Approach 1:
PEA demonstrates local quality through its selective bioactivity: it exerts strong anti-proliferative effects specifically on neoplastic and pre-neoplastic cells (ACF, adenomas) while showing minimal activity against healthy epithelial cells. This selectivity allows chemo-prevention to target only the pathological processes without compromising normal tissue function.
Solution Approach 2:
The patent utilizes parameter changes by modifying the physical state of PEA through ultra-micronization, reducing particle size to enhance solubility and bioavailability. This physical parameter change enables the substance to reach therapeutic concentrations in the colon while maintaining its selective biological properties.
3Reliability
If surgery is used to eradicate colorectal cancer, then tumor is removed, but conservative interventions and avoidance of ostomy are compromised
Solution Approach 1:
The patent applies preliminary action through chemo-prevention strategies that intervene before cancer develops or progresses to advanced stages. By administering PEA to prevent the formation of ACF, adenomas, and carcinoma, or to treat early-stage disease, the need for aggressive surgical interventions is reduced or avoided, enabling more conservative management.
Data Source
Figure 1~2B
Figure 2C~3A
Figure 3B~3C
AI summary
The present invention relates to the use of N-palmitoylethanolamide in the context of an antitumor therapy. In particular, the present invention relates to Palmitoylethanolamide for use in the prevention of colorectal carcinoma, adenomatous polyps and/or preneoplastic ACF lesions. Furthermore, the invention relates to palmitoylethanolamide for use in the antineoplastic therapy of colorectal carcinoma, in which said palmitoylethanolamide exerts a selective antiproliferative action on tumor cells and not on healthy cells.